Autofluorescence of choroidal vessels in Bietti’s crystalline dystrophy

Hossein Ameri, Erin Su, Tyler J Dowd-Schoeman

ABSTRACT

Objective To describe the pattern of fundus autofluorescence (FAF) in Bietti’s crystalline dystrophy (BCD).

Methods and analysis From the National Institutes of Health EyeGene database of 2769 patients with known pathogenic mutations, 5 patients with BCD-causing CYP4V2 mutations who had FAF images were selected. Demographic and genetic information and imaging files were obtained. From the FAF imaging files, unique autofluorescence (AF) patterns and correlation with retinal structures were assessed by three investigators for clinical significance.

Results Five patients (four males, one female; mean age 56 years, range 42–76 years) were included, all with different CYP4V2 mutations. All patients displayed varying degrees of hypo-AF in the posterior pole. In four out of five patients, there was a relative hyper-AF of choroidal vessels within the hypo-AF area; this feature was limited to sclerotic vessels only. A transitional zone of speckled AF was visible around the hypo-AF area. This zone corresponded to the area containing retinal crystals on colour fundus photography; however, retinal crystals did not demonstrate hyper or hypo-AF.

Conclusions This study presents a previously unreported characteristic finding in patients with BCD with CYP4V2 mutations. AF of choroidal vessels may aid in differentiating BCD from other retinal dystrophies.

INTRODUCTION

Bietti’s crystalline dystrophy (BCD) is a rare, progressive chorioretinal degenerative disease that affects an estimated 1/67 000 individuals, predominantly those of East Asian descent. Age of onset is typically in the third decade of life, with clinical manifestations of decreased visual acuity, night blindness and visual field loss, which may be central or peripheral. Ocular exam may reveal crystalline deposits in the cornea and/or retina and sclerosis of choroidal vessels. In late-stage BCD, the intraretinal crystals disappear and give way to chorioretinal and retinal pigment epithelium (RPE) atrophy, and typically patients become legally blind by their 40–50s. BCD is inherited in an autosomal recessive pattern, and is due to mutations in the CYP4V2 gene. CYP4V2 is ubiquitously expressed in various tissues in the body, including the cornea and retina, and encodes for Cytochrome P450 4V2, an enzyme that is responsible for fatty acid metabolism. The hallmark crystalline inclusions of BCD have also been found outside of ocular tissue, including circulating lymphocytes and skin fibroblasts, suggesting that BCD is caused by a systemic dysfunction of lipid metabolism. However, there is extreme variability in BCD disease presentation. For example, progression may be asymmetric between the two eyes, and individuals with the same CYP4V2 mutation may present differently. As such, with its rarity, early asymptomatic stages, painless progression and high variability, BCD can be difficult to diagnose and study. Previous imaging modalities have been used to better characterise BCD; these include fundus photography, near infrared reflectance, fluorescein angiography, fundus autofluorescence (FAF) and others.

FAF is an efficient, non-invasive clinical imaging modality that reflects RPE lipofuscin distribution, using a known wave length excitation to detect lipofuscin emissions. Lipofuscin naturally accumulates in the RPE over time as a byproduct of the incomplete degradation of photoreceptor outer segments. Though retinal lipofuscin accumulation is a hallmark of normal ageing,
abnormal patterns in lipofuscin density indicate certain retinal pathologies, and can be assessed accordingly with FAF. Previous clinical uses of FAF most prominently include age-related macular degeneration (AMD), which features abnormal lipofuscin accumulation, as well as many other macular dystrophies, including Stargardt disease and retinitis pigmentosa.

There are various FAF wavelengths used, short-wavelength versus near infrared; there are also different FAF imaging systems, including fundus camera, confocal scanning laser ophthalmoscopes and ultrawidefield technologies. Regardless of their different imaging strategies, all FAF technologies are able to act as metabolic mapping tools of the retina and assess RPE overall health or dysfunctions.

Previous studies have reported FAF changes in patients with BCD. This study presents autofluorescence (AF) changes in BCD with particular focus on previously undescribed AF findings in choroidal vessels.

**MATERIALS AND METHODS**

This is a retrospective study of the National Institutes of Health (NIH) EyeGene database. The deidentified data were obtained from the NIH EyeGene database, a DNA repository and patient registry of patients with inherited eye diseases from various institutions across the USA and Canada. Patients or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research. From 2769 patients with known pathogenic mutations, 10 patients with mutations in CYP4V2 causing BCD were selected. Five patients who did not have FAF images were excluded. Demographic information, genetic information and imaging files including colour fundus photo and FAF images of the five remaining patients were collected. FAF and colour images were then reviewed by three investigators for five remaining patients were collected. FAF and colour images of the five remaining patients were collected. FAF and colour images were then reviewed by three investigators for the presence of choroidal sclerosis and retinal crystals in those. In patient 2, all vessels were sclerotic and all showed relative hyper-AF. In patient 5, there was no choroidal sclerosis, and choroidal vessels were not visible on FAF; this patient only had geographical patches of hypo-AF, indicating less advanced disease compared with the others (figure 2).

In patient 4, there was a mixture of sclerotic and non-sclerotic vessels, and only sclerotic vessels showed AF

**RESULTS**

The study included five patients (table 1), four men and one woman, with a mean age of 56 years (range 42–76 years). Four out of five patients were non-Hispanic white and one was black. Mean age onset of night blindness was 48 years (range 32–64 years). Mean duration of night blindness was 11 years (range 4–21 years). Snellen visual acuity ranged from 20/30 to 20/200 in three patients; for the remaining two patients, no visual acuity was available.

Three out of five had bilateral corneal crystals. Four out of five patients had homozygous mutations, and one had compound heterozygous mutations, with no two patients sharing the same exact CYP4V2 mutation (table 1).

On evaluation of FAF images, posterior pole hypo-AF was observed in all patients, reflecting RPE atrophy (figure 1). In all but one patient (patient 5), the hypo-AF area was contiguous and involved the macula and peripapillary region. In these patients, choroidal vasculature was visible on FAF and demonstrated a relative hyper-AF compared with the surrounding hypo-AF area. Colour fundus photos were available for three patients (patients 2, 4 and 5), making it possible to assess for the presence of choroidal sclerosis and retinal crystals in those. In patient 2, all vessels were sclerotic and all showed relative hyper-AF. In patient 5, there was no choroidal sclerosis, and choroidal vessels were not visible on FAF; this patient only had geographical patches of hypo-AF, indicating less advanced disease compared with the others (figure 2). In patient 4, there was a mixture of sclerotic and non-sclerotic vessels, and only sclerotic vessels showed AF (figure 3). Patients 2, 4 and 5 showed a transitional zone of speckled AF surrounding the hypo-AF area; all of them displayed retinal crystals on colour fundus photos which corresponded to the speckled AF zone. However, retinal crystals did not consistently show hyper or hypo-AF (figure 2). Patients 1 and 3 showed irregularly shaped islands of relative hyper-AF within the hypo-AF area in a pattern somewhat similar to that in choroideraemia (figure IA,C).

**DISCUSSION**

Retinal pathologies, like BCD, present different patterns of hyper-AF and hypo-AF. Previous studies have reported FAF patterns in BCD, including diffuse or multilobular
hypo-AF of posterior pole, and hyper-AF and hypo-AF spots. An interesting finding in our study is AF of choroidal vasculature, which has not been previously reported. Fuerst et al. reported a patient with BCD with choroidal neovascularisation, and described 'tenuously hyper-AF' dots overlying the choroidal vessels seen on near-infrared FAF images in the contralateral eye. They also described mottled hypo-AF of the macula on short-wavelength FAF. A closer look at their FAF pictures, speckled AF with predominance of hypo-AF spots can be seen on short-wavelength FAF without any visibility of choroidal vessels. However, choroidal vessels are visible on the near-infrared FAF image and primarily display hypo-AF. Li et al. and Oishi et al. have also reported AF changes in BCD but neither have commented on AF of choroidal vasculature; however, on two of the patients presented in the Oishi et al. paper, AF of choroidal vasculature is evident on FAF images.

Despite the different FAF imaging systems and calibrations used to study patients, our FAF observations remain largely consistent between our patients, with FAF showing AF of choroidal vessels in four of five patients, giving the appearance of relative hyper-AF in the surrounding hypo-AF area. The only patient who did not show this feature was the one who had smaller area of RPE atrophy and no choroidal sclerosis on colour fundus photo, suggesting less advanced disease.

As to what causes AF of choroidal vessels is unclear. Choroidal sclerosis is one of the distinguished features of BCD, and this study shows that choroidal vascular AF is primarily seen when there is sclerosis. Presence of fibrotic changes in the choroid has been reported in BCD. Additionally, lipid materials, which often contain liposomal crystals, have been reported in conjunctival fibroblasts, circulating lymphocytes and choroidal fibroblasts of patients with BCD. The crystals themselves are less likely to be the source of AF, as retinal crystals do not display AF on short-wavelength FAF; lipid granules,
however, may contain fluorophores and show AF. We hypothesise that AF of choroidal vasculature in BCD is caused by fibroblasts and fibrotic materials around the large choroidal vessels which contain fluorophores, likely within the lipid granules. Detailed ultrastructural studies of vessel wall in patients with BCD with choroidal sclerosis may help to discover the source of AF and further expand our knowledge on the pathogenesis of the disease. Choroidal vessel sclerosis may also be seen in chorioretinopathy, which has some phenotypical resemblance to BCD.  

Zhang et al. reported significant plasma fatty acid abnormalities and prominent crystals in circulating lymphocytes suggesting presence of systemic disease in chorioretinopathy similar to BCD. In our study, we observed islands of relative hyper-AF within the central hypo-AF area, which is typically seen in chorioretinopathy. A study on the frequency of hyper-AF of choroidal vessels in chorioretinopathy and its potential association with choroidal sclerosis may further shed light on the pathogenesis of both diseases.

AF of choroidal vessels is not limited to BCD. Shinojima et al. reported hyper-AF of choroidal vessels within the macular atrophic area in over half of eyes with dry AMD and about 16% of eyes with macular dystrophy. The type of macular dystrophy was not specified and it is not known whether any of those patients had BCD. Their study found that choroidal thickness was significantly less in eyes that showed hyper-AF of choroidal vessels. Future large studies on BCD may explore any potential association between choroidal thickness and AF of choroidal vessels.

A common feature in our patients was hypo-AF of the posterior pole, suggesting diffuse loss of RPE and hence advanced disease. Additionally, we observed a transitional zone of speckled AF surrounding the hypo-AF area in those with wide field images. This finding is similar to the case presented by Fuerst et al. except that their case did not show a central area of hypo-AF at the posterior pole. We also noted the lack of any specific appearance of retinal crystalline deposits on FAF, which corroborates with the findings reported by Oishi et al.

There are some limitations to this study. First, the image bank was limited and each patient had one modality of FAF images, which varied between patients. However, this had some advantages in that we were able to demonstrate similar changes on different FAF modalities. Second, the study was retrospective, and we could not exactly determine the stage of the disease and establish at what point choroidal vessels started showing AF. Nevertheless, the display of large areas of hypo-AF at the posterior pole of most images indicates significant RPE loss and relatively advanced disease in the majority of patients. Third, this study included a small number of patients; larger studies are needed to show the frequency of our findings in patients with BCD.

In conclusion, this study demonstrates that, despite the inherent genotypic and phenotypic variability of BCD, FAF characteristics of BCD remain largely consistent. Relative hyper-AF of sclerotic choroidal vessels within the hypo-AF area of the posterior pole may aid in more affirmative clinical diagnosis of BCD in the absence of genetic testing or when genetic testing is inconclusive; particularly it can be useful in differentiating BCD from other crystalline retinopathies.

Acknowledgements We would like to thank the eyeGENE participants and the eyeGENE Research Group for their valuable contribution to this research.

Contributors HA: conception, data analysis and manuscript writing. ES: data analysis and manuscript writing. TJD-S: data collection, data analysis and manuscript revision.

Funding The data used for the analyses described in this paper were obtained from the National Eye Institute – National Ophthalmal Genotyping and Phenotyping Network (eyeGENE - Protocol EY-01-00236 which has been funded in part from the National Institutes of Health/National Eye Institute, under Contract No. N01-YS-260-2007-00001-C. Supported in part by an Unrestricted Grant to the Department of Ophthalmology from Research to Prevent Blindness, New York, NY.

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not required.

Ethics approval Institutional Review Board approval was obtained from the Office for the Protection of the Research Subjects of the University of Southern California (protocol number: HS-19-00040).

Provenance and peer review Not commissioned; internally peer reviewed.

Data availability statement All data relevant to the study are included in the article.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iD Hossein Ameri http://orcid.org/0000-0002-5270-2800

REFERENCES


